2013 Research Report of Accomplishments

109 Pages·2014·0.56 MB·English

Research Institute

Report of
Accomplishments

2013
Report of Accomplishments
Beaumont Health System
Research Institute

For more than 45 years, researchers at Beaumont have helped to bring new technologies, new
treatments, and new medications into the practice of medicine, and have helped to move the
standard of care forward to improve the safety and quality of medical care for patients locally,
nationally, and internationally. The greatest reward from these achievements is the realization
patients’ lives are improved and enriched because of the outstanding research carried out by
Beaumont physicians and staff.

Outstanding biomedical research is a major component of the excellent reputation of Beaumont
Health System as an academic medical center. The Board of Directors at Beaumont made a
commitment several decades ago to strengthen Beaumont as an academic institution through
growth and support of graduate medical education, the hiring of full time physicians with a history of
excellence in research, and committed support of ongoing research activities of key programs. This
commitment has helped to forge the reputation of Beaumont Health System as a leading academic
medical center, with recognition by U.S. News and World Report, a distinction which places
Beaumont in the forefront of medicine in the U.S.

As Beaumont Health System moves forward as the health care affiliate with the Oakland University
William Beaumont School of Medicine, our research activities, graduate medical education, and
scholarly endeavors are even more important. Our Board of Directors and senior leadership have
reaffirmed their commitment to this ongoing academic mission for Beaumont. Strong undergraduate
medical education requires faculty committed to research and a broad, excellent program of
graduate medical education. The ACGME (Accreditation Council on Graduate Medical Education) is
steadily increasing the requirements for excellence in both faculty research achievement and
resident/fellow/research training in order to maintain full accreditation for residency and fellowship
programs. The Board for Accrediting Level 1 Trauma Center status, presently achieved by Beaumont
Royal Oak, now requires productivity of peer-reviewed publications in recognized journals by
participating faculty. The LCME (Liaison Committee on Medical Education), the accrediting
organization for medical schools in the U.S. and Canada, requires the presence of biomedical
research activities that can provide both basic sciences and clinical research opportunities for
medical students. The OUWB medical school provides further impetus to enhance biomedical
research at both Beaumont and Oakland University, to integrate research activities between the two
institutions, and to initiate new programs, centers, and collaborative projects shared by both
institutions. Beaumont and Oakland University already have several areas of long standing ongoing
research collaboration.

Beaumont research is heavily oriented towards clinical translational research, investigating new
treatments, pharmaceuticals, medical devices, and scientific approaches aimed at enhancing the
excellence and safety of patient care. Beaumont has a robust program of clinical research,
numbering over 1,103 trials with over 620,293 registered research participants. Beaumont’s clinical
services are superb, providing the standard upon which new and innovative research is built. The
volume of patients served at Beaumont, combined with the excellence of clinical care, provides a
striking opportunity to develop new treatments.

The success of our commitment to excellent service and patient safety is shown by our receipt of full
accreditation of our human research protection program by AAHRPP (Association for Accreditation
of Human Research Protection Programs) on the first submission. Beaumont’s strategic plan calls
for initiatives which the well established national and international reputation achieved by some of
our research programs, including Cardiovascular Medicine, Radiation Oncology, Medical Oncology
(Hem/Onc), Urology, Orthopaedics, Ophthalmology, Anesthesiology, Surgery, Emergency Medicine,
and many other programs provide. We look forward to continuing research excellence and
productivity as Beaumont enters an exciting new phase of academic development. This Report of
Research Accomplishments highlights the depth and breadth of Beaumont’s academic excellence.
We extend our congratulations and appreciation to the many investigators who have contributed
these extraordinary achievements while providing outstanding medical care to our patients.
Beaumont Research Institute

Fact Sheet – 2013

Beaumont Health System, with three hospitals in the northern Detroit suburbs serving southern Michigan and beyond, is a highly
productive contributor to clinical trials across the nation. The Beaumont Research Institute (RI), established by the hospital’s
Board of Trustees in 1966, strengthens Beaumont's ability to conduct medical research and to provide a research training
experience for the medical staff and participants in graduate medical education programs.

Beaumont is a major teaching facility, with 40 accredited residency and fellowship programs involving 454 residents
and fellows, and 195 research staff, including 63 research nurses.

Funding Educational opportunities for research staff
♦ 2-day orientation for new research staff
2014 Research Institute Operations $34.0M
♦ On-line CITI human subjects protection training

program
External sources of research funding
(based on 2013 data) ♦ Tuition reimbursement for clinical research certification
♦ Commercial sponsors 36 % exams
♦ Federal sponsors 15 % ♦ Seminar Series and Workshops
♦ Philanthropic sponsors 13 % ♦ Residents' and Fellows' Research Forum
♦ Intellectual Property 36 % ♦ Online guidance/modules regarding initiating research

Types of research at Beaumont Health System
Facility space dedicated to research
(based on 2013 percentage of revenue)
• Clinical Research 50 % ♦ Research Institute Building
• 3 % Phase I ♦ Beaumont Health Center
• 28 % Phase II Phase based ♦ Cancer Center
• 69 % Phase III on HIC submission ♦ Imaging Center
• Pre-clinical/ Research 50 % ♦ Royal Oak Hospital
♦ Royal Oak Medical Office Building
♦ Technical Service Building
External sources of research funding by ♦ Troy Hospital
Research Service Line ♦ Other Offsite
(based on 2013 data)
• Surgical Services 43% Support staff available to researchers
♦ Radiation Oncology 25 % ♦ Accounting / Administrative
♦ Urology 6 % ♦ Beaumont Research Coordinating Center
♦ Surgical Clinical Trials & Lab 5 % ♦ BioBank/Erb Family Core Molecular Laboratory
♦ Orthopedics Bench 4 % ♦ Biosafety Committee
♦ Anesthesia 2 % ♦ Biostatisticians
♦ Other Programs (various) 1 % ♦ Commercialization Center
♦ Compliance
• Medical Services and Other 57% ♦ Database Development
♦ Emergency 5 % ♦ Education
♦ Hematology/Oncology 8 % ♦ Federal Grant Development
♦ Cardiology 10 % ♦ Human Resources
♦ Beaumont Coordinating Center. 5 % ♦ Institutional Animal Care and Use Committee (IACUC)
♦ Infectious Disease 2 % ♦ Institutional Review Board (IRB)
♦ Nutrition & Preventive Med 1 % ♦ Outcomes Research Group
♦ Other (Various) 26 %

• Clinical Trials/PIs/Research Participants
♦ 1,103 open trials
♦ 456 active principal investigators
♦ 620,293 registered research participants

The scope of support for the Research Institute
♦ Human Research Protection Program fully accredited
Beaumont Health System:
by AAHRPP
♦ More than 238,280 Emergency Center visits
♦ Automated, robotic clinical laboratories
♦ 98,401 Inpatient admissions
♦ Internationally recognized and respected principal
♦ 70 surgical suites
investigators
♦ A Flash CT scanner
♦ National Cancer Institute / Community Clinical
♦ PET-CT and biotracer
Oncology Program (CCOP)
♦ Beaumont Research Coordinating Center for ♦ Fully equipped bench laboratories
multicenter clinical trials
♦ State of the art BioBank & Core Molecular Lab
TABLE OF CONTENTS

ANESTHESIOLOGY and PERIOPERATIVE MEDICINE ................................................. 4-5

BIOBANK .......................................................................................................................... 6-9

CARDIOVASCULAR DISEASE .................................................................................... 10-15

COLON and RECTAL SURGERY ..................................................................................... 16

DIAGNOSTIC RADIOLOGY and MOLECULAR IMAGING .......................................... 17-24

EMERGENCY MEDICINE ............................................................................................. 25-29

FAMILY MEDICINE ....................................................................................................... 30-31

PATHOLOGY and LABORATORY MEDICINE ............................................................ 32-37

SUBSPECIALTY DIVISIONS OF INTERNAL MEDICINE ............................................ 38-56

ALLERGY .................................................................................................................... 39

GASTROENTEROLOGY and HEPATOLOGY ....................................................... 40-42

GENERAL INTERNAL MEDICINE .......................................................................... 43-47

GERIATRICS ................................................................................................................ 48

HEMATOLOGY / ONCOLOGY .................................................................................... 49

COMPREHENSIVE BREAST CARE CENTER ............................................................ 50

1
TABLE OF CONTENTS

INTERNAL MEDICINE continued

INFECTIOUS DISEASES ........................................................................................ 51-53

NEPHROLOGY ............................................................................................................ 54

NEUROLOGY .............................................................................................................. 55

NUTRITION and PREVENTIVE MEDICINE ................................................................. 56

PHYSICAL MEDICINE and REHABILITATION................................................................. 57

OBSTETRICAL / GYNECOLOGICAL SERVICES........................................................ 58-59

OPHTHALMOLOGY ..................................................................................................... 60-61

ORTHOPAEDIC SURGERY ......................................................................................... 62-69

PEDIATRIC SERVICES ................................................................................................ 70-73

PHARMACEUTICAL SERVICES……………………………………………………………......74

RADIATION ONCOLOGY ............................................................................................. 75-83

RESEARCH INSTITUTE ............................................................................................... 84-87

RESEARCH ADMINISTRATION............................................................................ . 85-87

2
TABLE OF CONTENTS

SUBSPECIALTY DIVISIONS OF SURGICAL SERVICES ........................................... 88-97

GENERAL SURGERY ................................................................................................. 89

MULTI-ORGAN TRANSPLANT ................................................................................... 90

NEUROSURGERY .................................................................................................. 91-92

OTOLARYNGOLOGY .................................................................................................. 93

PLASTIC SURGERY .................................................................................................... 94

PULMONARY and CRITICAL CARE ......................................................................... 95

TRAUMA SURGERY ................................................................................................... 96

VASCULAR SURGERY ............................................................................................... 97

UROLOGY .................................................................................................................. 98-106

Note: * Indicates the author(s) was not Beaumont staff at the time of publication, or was a Beaumont employee
at the time of the publication but has since left Beaumont.
3
ANESTHESIOLOGY AND PERIOPERATIVE MEDICINE

Peer-Reviewed Articles:

Hartrick CT. Long-term opioid treatment. Virtual Mentor. AMA Journal of Ethics.
2013;15(5):434-438.

Hartrick CT. Antidepressants for depressed patients with pain. Expert Opinion Invest Drugs.
2013;22(1):167-168.

Jongen JLM, Hans G, Benzon HT, Hartrick CT. Neuropathic pain and pharmacological
treatment. Pain Practice, published online June 10, 2013.

Abstracts from Scientific/Medical Meetings:

Hartrick CT. The role of glia in pain. Basic Science and Pathophysiology of Pain. ALGOS 2013
Kos, Greece, September 27, 2013.

Hartrick CT. Pharmacologic management of neuropathic pain. 15th Annual Pain Management
Symposium, Cleveland Clinic Foundation, Sarasota, FL, February 16, 2013.

Hartrick CT. Translating pain research into clinical practice. Pain Storm II: Assessment and
Management of Pain, Pain Management Academy of Puerto Rico Annual Meeting, San Juan,
Puerto Rico, February 23, 2013.

Hartrick CT. The role of microglia in pain. Basic Science and Pathophysiology of Pain, Algos.
International Symposium of WIP, Kos, Greece, September 26, 2013.

Hartrick CT. Opioid misuse and abuse: Risk mitigation strategies. 1st International Symposium:
Global Pain Suffering and Solutions to its Eradication, World Institute of Pain Foundation,
Kolkata, India, November 15, 2013.

Hartrick CT. Pain education of health professionals: Allied health professions. Pain Education I.
1st International Symposium: Global Pain Suffering and Solutions to its Eradication, World
Institute of Pain Foundation, Kolkata, India, November 16, 2013.

Hartrick CT, Wendell D, Pestano CP, Hartrick S, Qu G. CRPS following arthroscopic shoulder
surgery associated with IL1-ra genotype. American Society of Anesthesiology Annual Meeting,
San Francisco, CA, October 12-16, 2013.

Hartrick CT, Wendell D, Pestano CP, Hartrick S, Qu G. Persistent postsurgical pain following
arthroscopic shoulder surgery associated preoperative anxiety and somatization. American
Society of Anesthesiology Annual Meeting, San Francisco, CA, October 12-16, 2013.

4
Anesthesiology and Perioperative Medicine

Abstracts from Scientific/Medical Meetings: continued

Hartrick CT, Mounayer MH, Pestano CP, Hartrick S, Qu G, Knapke D. Effect of adding
intraarticular analgesics and sciatic block to continuous femoral block for total knee arthoplasty.
American Society of Anesthesiology Annual Meeting, San Francisco, CA, October 12-16, 2013.

Pestano CP. Nurse-rated ease of questionnaire, satisfaction, and patient mobility with Fentanyl
Iontophoretic Transdermal System (Fentanyl ITS) versus IV PCA morphine for post-operative
pain management: A pooled analysis of 3 randomized, controlled trials. American Society of
Perianesthesia Nurses National Conference, Chicago, IL, April 13-17, 2013.

Qu G, Hartrick CT, Silvasi D. APSiS: Discovering knowledge from electronic medical records
for Healthcare Health Care Forum: The Physician’s Practice: Emerging Issues for Providers.
Thomas M. Cooley Law School, Auburn Hills, MI, May 9, 2013.

5
BIOBANK

Peer-Reviewed Articles:

Akervall J, Pruetz BL, Geddes TJ, Larson D, *Felten DL, Wilson GD. Beaumont Health
System BioBank: A multidisciplinary biorepository and translational research facility.
Biopreservation and Biobanking, 11(4): 221-228, 2013.

Akervall J, Nandalur S, Zhang J, Qian CN, Goldstein N, Gyllerup P, et al, [Wilson GD]. A novel
panel of biomarkers predicts radioresistance in patients with squamous cell carcinoma of the
head and neck. European Journal of Cancer, published online December 9, 2013.

Baschnagel A, Wilson GD, Akervall J, Williams L, Hanna A, Pruetz B, et al. C-Met expression
is a marker of poor prognosis in patients with locally advanced head and neck squamous cell
carcinoma treated with chemoradiation. International Journal of Radiation Oncology Biology
Physics, published online November 6, 2013.

Geddes TJ, Ahmed S, Pruetz BL, Larson DM, Thibodeau BJ, Akervall J, et al, [Wilson GD].
SPIN: Development of sample-specific protein integrity numbers as an index of biospecimen
quality. Biopreservation and Biobanking 11(1):25-32, 2013.

*Gillies C, Patel N, Akervall J, Wilson GD. Gene expression classification using binary rule
majority voting genetic programming classifier. International Journal of Advanced Intelligence
Paradigms, Vol 4, No.3/4, 241-255, 2013.

*Gillies CE, Siadat MR, Patel NV, Wilson GD. A simulation to analyze feature selection
methods utilizing gene ontology for gene expression classification. Journal Biomedical
Information 46(6):1044-59, 2013.

Masterson L, Thibodeau BJ, Fortier L, Geddes TJ, Pruetz BL, Malhotra RK, et al, [Wilson
GD]. Gene expression differences predict treatment outcome of merkel cell carcinoma patients.
Journal of Skin Cancer, published online December 4, 2013.

Nagar S, Ahmed S, Peeples C, Urban N, Boura J, Thibodeau BJ, et at, [Akervall J, Wilson
GD]. Evaluation of genetic biomarkers for distinguishing benign from malignant thyroid
neoplasms. American Journal of Surgery, published online October 28, 2013.

Pezeshkian P, Donnelly C, Tamburo K, Geddes TJ, Madlambayan G. Leukemia mediated
endothelial cell activation modulates leukemia cell susceptibility to chemotherapy through a
positive feedback loop mechanism. PLoS One, published online April 1, 2013.

Schwartz JD, Dumler F, Hafron JM, Wilson GD, Rooney MT, Li W, et al. CD133 staining
detects acute kidney injury and differentiates clear cell papillary renal cell carcinoma from other
renal tumors. ISRN Biomarkers, published online June 2013.

Wilson GD, Marples B, Galoforo S, Geddes TJ, Thibodeau BJ, Grenman R, et al, [Akervall J].
Isolation and genomic characterization of stem cells in head and neck cancer. Head Neck
35(11):1573-82, 2013.

6
BioBank

Peer-Reviewed Articles: continued

Zhang PL, Mashni JW, Sabbisetti VS, Schworer CM, Wilson GD, Wolforth SC, et al, [Geddes
TJ]. Urine kidney injury molecule-1: A potential non-invasive biomarker for patients with renal
cell carcinoma. Int. Urol. Nephrol, published online August 25, 2013.

Book Chapter or Full Book Publications:

Akervall J. Minimally invasive head and neck surgery. In: Essentials of Robotic Surgery, Edited
by Drs. Sood M and Leichtle SW, 2013 Spry Publishing, Chapter 15: 239-248.

Abstracts from Scientific/Medical Meetings:

Akervall J, Chen P, Noujaim S. Innovative management of recurrent head and neck cancer. 3rd
Annual Symposium on Multidisciplinary Approach to Head and Neck Cancer Management,
Birmingham, MI, September 13, 2013.

Baschnagel AM, Galoforo S, Thibodeau BJ, Ahmed S, Akervall J, Wilson GD. C-met as a
target for radiation enhancement in head and neck squamous cell carcinomas. 43rd Annual
Beaumont Health System Residents’ and Fellows’ Research Forum, Royal Oak, MI, June 5,
2013. Annual Meeting of the American Society for Radiation Oncology, Atlanta, GA, September
22-25, 2013. International Journal of Radiation Oncology Biology Physics 87(2) Supplement,
S649-S650.

Baschnagel AM, Thibodeau BJ, Williams L, Fortier L, Ketelsen B, Pruetz BL, et al, [Akervall
J, Wilson GD]. Comparison of gene expression profiles of pretreatment and recurrent locally-
advanced head and neck squamous cell carcinomas treated with chemoradiation. Annual
Meeting of the American Society for Radiation Oncology, Atlanta, GA, September 22-25, 2013.
International Journal of Radiation Oncology Biology Physics 87(2), Supplement, S666.

Fulton M, Hafron J, Thibodeau BJ, Zhang P, Geddes TJ, Fortier L, Wilson GD. Identification
of molecular processes regulating aggressiveness of clear cell renal cell carcinoma. 87th Annual
Meeting of the North Central Section of the American Urological Association, Naples, FL,
October 8-13, 2013.

Fulton M, Hafron J, Thibodeau BJ, Zhang P, Geddes TJ, Fortier L, Wilson GD. Gene
expression analysis of clear cell renal cell carcinoma: Identification of candidate serum
biomarkers. 87th Annual Meeting of the North Central Section of the American Urological
Association, Naples, FL, October 8-13, 2013.

Geddes TJ. The new generation of biorepository sample quality assessment for downstream
analyses: The SMART and SPIN metrics. 5th International Leaders in Biobanking Congress,
Indianapolis, IN, November 4, 2013.

7